Preventing Venous Thromboembolism in Ambulatory Cancer Patients: The ONKOTEV Study

Cella, Chiara Alessandra; Minno, Giovanni Di; Carlomagno, Chiara; Arcopinto, Michele; Cerbone, Anna Maria; Matano, Elide; Tufano, Antonella; Lordick, Florian; Simone, Biagio De; Muehlberg, Katja; Bruzzese, Dario; Attademo, Laura; Arturo, Claudia; Sodano, Marta; Moretto, Roberto; Fata, Ersilia La; Placido, Sabino De

doi:10.1634/theoncologist.2016-0246

Cited by 123 publications

(109 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Khorana score was the first validated risk assessment model (RAM) for identifying VTE high-risk patients receiving chemotherapy. After this publication, different RAM have been published and some of them have been validated (Table 3) [24][25][26][27][28][29][30][31][32]. Other RAM addressed to specific tumors such as THROLY [33] or testicular germ cell tumors [34].…”

Section: Prophylaxis Of Vte In Ambulatory Cancer Patients During Systmentioning

confidence: 99%

“…Compared to LMWH or UFH, fondaparinux was not statistically different in all endpoints including mortality, recurrence VTE, and bleeding. In the second meta-analysis [53], a subgroup analysis of cancer patients Vienna CATS score [25] PROTECHT score [26] CONKO score [27] Oncothromb-Tic Onco score extended [28,29] Compass-CAT score [30] a Onkotev score [31] Pabinger et al [32] Tumor vascular/ lymphatic compression reported a significant reduction in mortality with LMWH compared to UFH (OR 0.53, 95% CI 0.33-0.85; p = 0.009).…”

Section: Initial Treatment Of Vte In Cancer Patients (5-10 Days)mentioning

confidence: 99%

See 1 more Smart Citation

SEOM clinical guideline of venous thromboembolism (VTE) and cancer (2019)

et al. 2020

View full text Add to dashboard Cite

In 2011, the Spanish Society of Medical Oncology (SEOM) first published a clinical guideline of venous thromboembolism (VTE) and cancer. This guideline was updated in 2014, and since then, multiple studies and clinical trials have changed the landscape of the treatment and prophylaxis of VTE in cancer patients. To incorporate the most recent evidence, including data from direct oral anticoagulants (DOACs) randomized clinical trials, SEOM presents a new update of the guideline.

show abstract

Section: Prophylaxis Of Vte In Ambulatory Cancer Patients During Systmentioning

confidence: 99%

Section: Initial Treatment Of Vte In Cancer Patients (5-10 Days)mentioning

confidence: 99%

SEOM clinical guideline of venous thromboembolism (VTE) and cancer (2019)

et al. 2020

View full text Add to dashboard Cite

show abstract

“…of high-risk patients were diagnosed with VTE within months of initiating chemotherapy (25,38). We utilized a prespecified VTE-independent adjudication committee that included a central radiology review of all radiographic studies indicative of a thrombotic event.…”

Section: L I N I C a L M E D I C I N Ementioning

confidence: 99%

Targeting protein disulfide isomerase with the flavonoid isoquercetin to improve hypercoagulability in advanced cancer

et al. 2019

View full text Add to dashboard Cite

“…The ONKOTEV score [89] was developed using a large multicenter prospective cohort of 843 cancers patients. Overall, 73 (8.6%) VTE events occurred during a median follow-up of 8.3 months.…”

Section: Risk Assessment Models (Ram) For Prediction Of Vte In Patienmentioning

confidence: 99%

Primary Thromboprophylaxis in Pancreatic Cancer Patients: Why Clinical Practice Guidelines Should Be Implemented

Farge

Bournet

Conroy

et al. 2020

Cancers

View full text Add to dashboard Cite

Exocrine pancreatic ductal adenocarcinoma, simply referred to as pancreatic cancer (PC) has the worst prognosis of any malignancy. Despite recent advances in the use of adjuvant chemotherapy in PC, the prognosis remains poor, with fewer than 8% of patients being alive at 5 years after diagnosis. The prevalence of PC has steadily increased over the past decades, and it is projected to become the second-leading cause of cancer-related death by 2030. In this context, optimizing and integrating supportive care is important to improve quality of life and survival. Venous thromboembolism (VTE) is a common but preventable complication in PC patients. VTE occurs in one out of five PC patients and is associated with significantly reduced progression-free survival and overall survival. The appropriate use of primary thromboprophylaxis can drastically and safely reduce the rates of VTE in PC patients as shown from subgroup analysis of non-PC targeted placebo-controlled randomized trials of cancer patients and from two dedicated controlled randomized trials in locally advanced PC patients receiving chemotherapy. Therefore, primary thromboprophylaxis with a Grade 1B evidence level is recommended in locally advanced PC patients receiving chemotherapy by the International Initiative on Cancer and Thrombosis clinical practice guidelines since 2013. However, its use and potential significant clinical benefit continues to be underrecognized worldwide. This narrative review aims to summarize the main recent advances in the field including on the use of individualized risk assessment models to stratify the risk of VTE in each patient with individual available treatment options.

show abstract

Preventing Venous Thromboembolism in Ambulatory Cancer Patients: The ONKOTEV Study

Cited by 123 publications

References 36 publications

SEOM clinical guideline of venous thromboembolism (VTE) and cancer (2019)

SEOM clinical guideline of venous thromboembolism (VTE) and cancer (2019)

Targeting protein disulfide isomerase with the flavonoid isoquercetin to improve hypercoagulability in advanced cancer

Primary Thromboprophylaxis in Pancreatic Cancer Patients: Why Clinical Practice Guidelines Should Be Implemented

Contact Info

Product

Resources

About